Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Mark Blaine Geyer, MD, Jae H. Park, MD, Isabelle Riviere, PhD, Brigitte Senechal, PharmD, PhD, Xiuyan Wang, PhD, Terence J. Purdon, Michel W. Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2016) 128 (22): 58.

https://doi.org/10.1182/blood.V128.22.58.58

Published: 2016

Journal Articles

Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease

Melody Smith, MD, Arnab Ghosh, MD PhD, Scott James, MD PhD, Marco L Davila, MDPhD, Enrico Velardi, PhD, Kimon V. Argyropoulos, MD, Gertrude Gunset, Andrea Schietinger, PhD, Michel W. Sadelain, MD PhD, Marcel van den Brink, MD PhD

Blood (2016) 128 (22): 653.

https://doi.org/10.1182/blood.V128.22.653.653

Published: 2016

Journal Articles

Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo.

Il-Kang Na, MD, John Markley, MD, PhD, Jennifer Tsai, MD, Nury L. Yim, Bradley J. Beattie, Alexander D. Klose, PhD, Amanda M. Holland, Arnab Ghosh, MD, PhD, Uttam K. Rao, Matthias Stephan, MD, PhD, Inna Serganova, PhD, Renier J. Brentjens, MD, PhD, Ron R.G. Blasberg, MD, Michel W Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2009) 114 (22): 914.

https://doi.org/10.1182/blood.V114.22.914.914

Published: 2009

Journal Articles

Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells.

Renier J. Brentjens, MD, PhD, Daniel Hollyman, PhD, Jae Park, MD, Elmer Santos, MD, PhD, Raymond Yeh, Ph.D., Jolanta Stefanski, Clare Taylor, PhD, Mark A. Weiss, MD, Daniel Filippa, MD, Isabelle Riviere, PhD, Michel W Sadelain, MD, PhD

Blood (2009) 114 (22): 3436.

https://doi.org/10.1182/blood.V114.22.3436.3436

Published: 2009

Journal Articles

Generation of T Cells of Desired HLA Restriction Specific for Epitopes of a Self-Antigen, WT1, for the Adoptive Immunotherapy of WT1 Positive Malignancies Using A Panel of Artificial Antigen Presenting Cells Expressing Prevalent HLA Alleles.

Ekaterina Doubrovina, MD, PhD, Aisha Hasan, MD, Banu Oflaz-Sozmen, MD, Annamalai Selvakumar, Michel W Sadelain, MD, PhD, Richard J O'Reilly, MD

Blood (2009) 114 (22): 4086.

https://doi.org/10.1182/blood.V114.22.4086.4086

Published: 2009

Journal Articles

Strategies for Therapeutic Peptide Delivery by Mesenchymal Stem Cells

Xian-Yang Zhang, PhD, Lisa To, BA, Jakob Reiser, PhD, Charles S. Hemenway, MD, PhD, Michel W Sadelain, MD, PhD, Vincent F. La Russa, PhD

Blood (2008) 112 (11): 863.

https://doi.org/10.1182/blood.V112.11.863.863

Published: 2008

NARROW

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease

Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo.

Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells.

Generation of T Cells of Desired HLA Restriction Specific for Epitopes of a Self-Antigen, WT1, for the Adoptive Immunotherapy of WT1 Positive Malignancies Using A Panel of Artificial Antigen Presenting Cells Expressing Prevalent HLA Alleles.

Strategies for Therapeutic Peptide Delivery by Mesenchymal Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease

Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo.

Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells.

Generation of T Cells of Desired HLA Restriction Specific for Epitopes of a Self-Antigen, WT1, for the Adoptive Immunotherapy of WT1 Positive Malignancies Using A Panel of Artificial Antigen Presenting Cells Expressing Prevalent HLA Alleles.

Strategies for Therapeutic Peptide Delivery by Mesenchymal Stem Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only